Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $197.43, a high estimate of $246 ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose (HD) version of the ...

Key recent performance and business profile Biogen (BIIB) has moved quietly higher, with the share price showing a 0.8% decline over the last day but gains of 1.5% over the past week and 18.1% over ...

Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer's drug, Leqembi, ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market ...